How Epstein-Barr Virus affects cell metabolism and gene expression
Regulation of EBV Latency by Purine Metabolism and Signaling
This study looks at how the Epstein-Barr Virus affects the way certain immune cells work, which could help us understand how the virus can stay in the body and possibly lead to cancer, with the hope of finding new ways to treat related illnesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11079623 on NIH RePORTER |
What this research studies
This research investigates how the Epstein-Barr Virus (EBV) alters the metabolism and gene expression of host cells, particularly focusing on B-lymphocytes. By examining the role of specific viral proteins in regulating purine metabolism, the study aims to uncover the mechanisms that allow EBV to establish latency and contribute to tumor formation. The research employs advanced techniques to analyze gene expression and metabolic pathways, providing insights into the viral oncogenesis process. Patients may benefit from a better understanding of EBV-related diseases and potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals with EBV-related conditions or those at risk for EBV-associated malignancies.
Not a fit: Patients without any history of EBV infection or related health issues may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for diseases associated with EBV, including certain cancers.
How similar studies have performed: Other research has shown success in understanding viral mechanisms in oncogenesis, suggesting that this approach may yield valuable insights.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Tempera, Italo — Wistar Institute
- Study coordinator: Tempera, Italo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.